Form 4: SpringWorks Therapeutics Executive Bhavesh Ashar Reports Stock and Option Grants
SEC Form 4
Bhavesh Ashar, Chief Commercial Officer of SpringWorks Therapeutics, reports the acquisition of restricted stock units and stock options.
Summary
- On January 10, 2025, Bhavesh Ashar, Chief Commercial Officer of SpringWorks Therapeutics, was granted 17,323 restricted stock units (RSUs) and options to purchase 50,615 shares of common stock.
- The RSUs vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and 34% on January 10, 2028, contingent upon continued service.
- The stock options vest in 48 equal monthly installments starting January 10, 2025, also contingent upon continued service.
- Following these transactions, Ashar directly owns 63,069 shares of SpringWorks Therapeutics common stock and options to purchase 50,615 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, incentivizing management and aligning their interests with shareholders.
Positives
- The grant of RSUs and stock options aligns the executive's interests with the long-term performance of the company.
- The vesting schedules incentivize continued service and commitment from the Chief Commercial Officer.
Industry Context
Stock option and RSU grants are common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biopharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules are typical, designed to retain executives over a multi-year period.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: grant of RSUs and stock options |
| 01/10/2026 | First vesting date for 33% of RSUs |
| 01/10/2027 | Second vesting date for 33% of RSUs |
| 01/10/2028 | Final vesting date for 34% of RSUs |
| 01/10/2035 | Expiration date of stock options |
| 01/14/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.